1 Jul 2020Review
Male breast cancer: an update
Giacomo Benassai 1Andrea Miletti 2Francesca Calemma 2Ermenegildo Furino 3Giovanni Palma 2Gennaro Quarto 2
Affiliations
Article Info
1 Department of Clinical Medicine and Surgery, “Federico II” University, Naples, Italy – I.A.D. Integrated Activity Department (I.A.D.) of Digestive System Disease
2 Department of Clinical Medicine and Surgery, “Federico II” University, Naples, Italy – I.A.D. Integrated Activity Department (I.A.D.) of Digestive System Diseases
3 Emergency-Admission Department Reunited Hospitals Nola, Naples3-South A.S.L, Campania Region, Italy
Ann. Ital. Chir., 2020, 91(4), 359-365;
Published: 1 Jul 2020
Copyright © 2020 Annali Italiani di Chirurgia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
PURPOSE: To summarize and compare the most recent data from the literature to clarify the management of male breast cancer. METHODS: A review article. RESULTS: Diagnosis and Treatment of Male Breast Cancer have been derivative for years. Nowadays MBC is a nosological entity in its own right with biological, molecular and clinical features that require a multidisciplinary approach and the involvement of specific skills. Multimodal treatment involves surgery, radiotherapy and chemotherapy. It is evident that the outcome of the MBC is worse than the female one. MBC is often diagnosed in advanced stages. Screening programs in the male population need to be strengthened to obtain an earlier diagnosis. It is necessary to know even more in depth the endocrine-metabolic and behavioral risk factors related to the neoplasm. Finally in the coming years it is reasonable to expect an improvement in multigenic tests: the sensitivity of these methods could predict the risk of recurrence even more precisely. This could lead to substantial changes in the choice and duration of treatment with results that could be surprising.
Keywords
- Male breast cancer
- Management
- Review
- Update